843.1 - NOS isoforms facilitate Ca2+ -cycling-dependent and -independent cardiac contractility - - Board: B169-170
Saturday, April 2, 2022
6:00 PM – 7:30 PM
Room: Exhibit/Poster Hall A-B - Pennsylvania Convention Center
Introduction: During the EB Welcome Reception, we will highlight 50 of the over 4,000 scientific posters to be presented later in the conference. All disciplines will be represented.
Ying Wang (University of California), MeiMi Zhao (University of California), Gabriela Rivera (University of California), Bing Xu (University of California), Vaseem Mir (University of California), Raghu Reddy (University of California), Yang Xiang (University of California)
Increasing biased G-protein coupled receptor (GPCR) drugs are now under clinical investigation. More understanding of the biased β-adrenergic receptor (β-AR) signaling is urgently required for a better cardiovascular drug. Here we found that two nitric oxide synthase (NOS) isotypes, NOS1, and NOS3 coupled with β1ARs and transduce distinct β1AR-cGMP signaling at sarcoplasmic reticulum and myofilament microdomain, respectively. Intriguingly, activation of NOS1 enhanced contractility and Ca2+ cycling, whereas NOS3 promoted contraction without affecting intracellular Ca2+. Quantitative proteomic revealed that NOS3 activation increased phosphorylation of myosin proteins including myosin binding protein C (MyBP-C), myosin light chain kinase (MYLK) and myosin phosphatase target subunit 1 (MYPT1), to enhance contractility by Ca2+sensitization. Moreover, in heart failure, excessive adrenergic stimulation dissociated β1AR from NOS1 and impaired the NOS1-cGMP signaling. Accordingly, stimulating NOS3 but NOS1 enhances systolic cardiac contraction in failing mice without rousing intracellular Ca2+. We propose NOS facilitate biased β1AR-cGMP signaling via Ca2+-dependent or independent mechanisms and define NOS3-cGMP as specific therapeutic strategy targeting myofilament for heart failure.
Support or Funding Information
American Heart Association (AHA) Postdoctoral Fellowship (YW 830512)